SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

The Mullen Army Token originated from a dedicated community of retail investors who faced challenges in the traditional stock market. We united to create a cryptocurrency that embodies our principles and aspirations for a fair financial system.     We provide a platform for retail investors to engage in a transparent and fair financial market. Our efforts include grassroots marketing, community engagement, and educational content to empower our investors.

MullenArmy

The MullenArmy symbol is currently trending as speculative investors debate whether this Solana-based project will replicate the extreme volatility and parabolic runs of previous cycles. While proponents urge community-led accumulation and hype to trigger a comeback, vocal critics warn of potential rug pulls and label the asset a recurring scam modeled after past market failures.

What is Amp?  Amp is described as the new digital collateral token offering instant, verifiable assurances for any kind of value transfer. Using Amp, networks like Flexa can quickly and irreversibly secure transactions for a wide variety of asset-related use cases.  How does Amp work?  Amp claims to offer a straightforward but versatile interface for verifiable collateralization through a system of collateral partitions and collateral managers. Where collateral partitions can be designated to collateralize any account, application, or even transaction, and carry balances which are directly verifiable on the Ethereum blockchain, collateral managers are smart contracts that can lock, release, and redirect collateral in these partitions as needed in order to support value transfer activities. Amp supports a wide variety of use cases for collateralization, and also introduces the concept of predefined partition strategies, which can enable special capabilities such as collateral models through which tokens can be staked without ever leaving their original address.

AMP Token

AMP is trending as investors remain polarized, with some anticipating significant price appreciation fueled by the potential passage of the Clarity Act and institutional adoption, while others condemn the project as a long-term failure and a scam. Community discourse is dominated by intense debates between 'bag holders' hoping for a breakthrough in payment infrastructure and vocal bears who point to years of consistent decline as evidence that the token has no future.

Maul Coin

Maul Coin is generating significant community buzz and price volatility as investors push to break through resistance levels and secure a chart listing on tracking platforms. The project is being championed by an active developer and a dedicated base of holders who are heavily promoting the coin across social media to fuel a potential breakout.

Algorand is a scalable, secure, and decentralized digital currency and smart contract platform. Its protocol uses a variation of Proof-of-Stake (PoS) called Pure PoS (PPoS) to secure the network and reach consensus on block production. Developers can build decentralized applications (dApps) using familiar programming languages, including Python, which Algorand supports natively. Its infrastructure enables various use cases, including payment systems, digital identity solutions, supply-chain tracking, and financial services. The protocol's architecture allows for tokenization of assets and the development of smart contracts, while its technical specifications support both retail users seeking basic transaction capabilities and enterprises requiring more, complex, blockchain solutions.

Algorand

Algorand is currently a focal point for community discussion as investors debate its long-term potential versus recent price volatility, with many highlighting its post-quantum security features and institutional moves as catalysts for future growth. While some traders are actively monitoring entry points for accumulation, others are expressing frustration over the project's extended drawdown and shifts in the broader digital asset landscape.

Pulse Biosciences, Inc. operates as an immuno-oncology company developing a proprietary oncolytic electroceutical therapy based on its Nano Pulse Stimulation (NPS) technology. It manufactures surgical and medical instruments using a novel and proprietary platform technology called Nano-Pulse Electro-Signaling. The NPES provides local tumor control and initiates an adaptive immune response with a vaccine-like effect by inducing immunogenic apoptosis of the cells. The company was founded on May 19, 2014 and is headquartered in Miami, FL.

Pulse Biosciences Inc

Pulse Biosciences is capturing investor attention as the company advances its proprietary Nanosecond Pulsed Field Ablation (nsPFA) technology, with the community actively monitoring positive clinical trial data and potential breakthrough developments in cardiac and soft tissue treatment. Investors are closely tracking strategic insider activity and long-term clinical trial milestones, frequently discussing the potential for a transformative breakthrough in the atrial fibrillation market.

XRP is a decentralized digital asset and the native token of the XRP Ledger, a Layer 1 blockchain designed for high-performance global payments. Its primary value proposition is offering a fast, cost-effective alternative to traditional banking systems by enabling near-instant cross-border settlements that finalize in three to five seconds. By serving as a neutral bridge asset between different fiat currencies, it helps financial institutions lower liquidity costs and eliminates the need for pre-funded accounts.  The network is unique because it utilizes a federated consensus protocol instead of energy-intensive mining or staking. This system achieves deterministic finality through a Unique Node List of trusted validators who must reach an eighty percent agreement threshold to permanently record transactions. This infrastructure supports a sustained throughput of 1,500 transactions per second and includes a built-in decentralized exchange that allows for the automated trading of any tokenized asset without intermediaries.  The project traces its origins back to 2004 with Ryan Fugger before being co-founded in its modern form by Jed McCaleb and Chris Larsen. The company, now known as Ripple, works with major financial institutions as partners and investors to build global payment solutions. To protect the network from spam, a small amount of XRP is burned during every transaction, and the token is further utilized by institutions as collateral to access traditional markets and manage digital asset infrastructure.  Institutional adoption of the asset reached a major milestone in November 2025 when the SEC approved the first wave of spot XRP ETFs. These products, offered by major issuers including Bitwise, Grayscale, 21Shares, Canary Capital, and Franklin Templeton, are now listed on prominent exchanges like the NYSE Arca, Nasdaq, and Cboe BZX. While Ripple remains a key contributor to the ecosystem, the underlying XRP Ledger continues to operate as an open-source and decentralized network.

Ripple

The XRP community remains deeply divided, with bulls pointing to ongoing Ripple developments and anticipation of the Clarity Act as long-term catalysts, while bears focus on stagnant price action and frustration over Ripple's token management. Despite the ongoing market volatility, discussion is dominated by debates over institutional adoption, the role of stablecoins on the XRP Ledger, and whether the asset can maintain its relevance in a shifting regulatory landscape.

COTI is a fast and light confidentiality layer on Ethereum. Powered by the breakthrough cryptographic protocol Garbled Circuits and secured by Ethereum, COTI introduces the most advanced and compliant solution for data protection on the public blockchain. Paving the way for the next wave of Web3 innovation and adoption, COTI unlocks a whole new world of use cases, including confidential transactions, Artificial Intelligence, DeFi, decentralized identification, and more.

COTI

COTI is gaining significant momentum and attention as the community rallies around its innovative garbled circuits technology and the recent transition to mainnet. Investors are actively discussing the protocol's potential to provide programmable, compliant privacy for real-world assets, with many highlighting its perceived competitive edge and growth potential in the evolving privacy sector.

Vanguard International Equity Index Funds - Vanguard FTSE Europe ETF

Vanguard FTSE Europe ETF

Vanguard FTSE Europe ETF (VGK) is facing heightened volatility as investors grapple with shifting geopolitical tensions, energy inflation fears, and the European Central Bank's potential path toward forced hawkishness. While some community members are using the fund for long-term geographic diversification to mitigate U.S. concentration risk, others are expressing concern over the economic impact of regional instability and are debating whether to hedge or reduce exposure during this period of uncertainty.

iShares Trust - iShares Russell 2000 Value ETF

iShares Russell 2000 Value ETF

The iShares Russell 2000 Value ETF ($IWN) is trending as investors debate the impact of potential new tariffs on steel and aluminum imports, leading to increased focus on how these policy shifts will influence small-cap valuations and supply chain costs. Community discussions are currently dominated by concerns over whether these trade measures will spark a domestic economic slowdown or if the small-cap sector offers a resilient rotation opportunity amid ongoing market volatility.

Virtuals Protocol is a launchpad platform launched in 2024 that enables users to create, tokenize, and monetize AI agents for gaming, entertainment, and virtual environments without requiring technical expertise. Initially built on Ethereum's Base Layer 2 network, the protocol has expanded to Ethereum mainnet, Solana, and Ronin as of 2025. VIRTUAL serves as the base liquidity pair and transactional currency for all AI agent interactions across the ecosystem.  The protocol operates through a bonding curve system where new AI agents are created with a 100 VIRTUAL fee. Users can buy and sell agent tokens until the agent reaches 42,000 VIRTUAL, at which point it graduates to a permanent liquidity pool paired with VIRTUAL. AI agents are multimodal, capable of text, speech, and 3D animation, and can manage on-chain wallets autonomously. Notable examples include Luna, an AI girl band vocalist with over 500,000 TikTok followers. The GAME framework powers agent functionality, enabling them to process inputs, generate responses, and remember past interactions.  Virtuals Protocol was founded by Jansen Teng and Weekee Tiew, evolving from PathDAO, a gaming guild established in 2021 that pivoted to AI agents in January 2024. The team raised $16 million in seed funding led by DeFiance Capital and Beam. In 2025, major partnerships were announced with Animoca Brands and a collaboration with Zyfai and BasisOS to launch an Agentic Fund of Funds.  Users can stake VIRTUAL tokens for veVIRTUAL to participate in DAO governance and may receive airdrops of agent tokens. When users interact with agents, they pay fees in VIRTUAL that generate protocol revenue. This revenue funds periodic buybacks and burns of the VIRTUAL token, reducing its total supply as a value-accrual mechanism for holders.

Virtual Protocol

Virtual Protocol is currently a major focal point for community discussion due to its pivotal role in the 'agentic AI' narrative and recent volatility that has traders debating whether it is a long-term accumulation play or a speculative pump-and-dump. While proponents highlight its potential for multi-year growth as an infrastructure layer for autonomous AI agents, many vocal participants remain skeptical, expressing frustration over persistent selling pressure and aggressive market fluctuations.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

A Key "Master" Protein That Declines by Half After Age 40. One Company Found a Way to Restore It.

A Key 'Master' Protein That Declines by Half After Age 40. One Company Found a Way to Restore It. A Key 'Master' Protein That Declines by Half After Age 40. One Company Found a Way to Restore It. PR...

Longeveron (LGVN) Q4 2025 Earnings Call Transcript

@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo...

Longeveron Braces For Q4 Results Following Recent Funding Boost

Longeveron Inc. shares are trading higher Tuesday as investors pivot their focus toward the company's Q4 earnings report, due after the bell.read more...

Longeveron (LGVN) Shares Surge On $30 Million Private Placement Deal

Longeveron shares are trading sharply higher Tuesday afternoon following the announcement of a private placement agreement worth up to $30 million.read more...

Best Biotech Stocks To Keep An Eye On - March 10th

Vertex Pharmaceuticals, BioNTech, Danaher, Longeveron, Moderna, United Therapeutics, and argenex are the seven Biotech stocks to watch today, according to MarketBeat's stock screener tool. Biotech...

<ul class="summary-bullets"><li>The company said that laromestorcel infusions resulted in clinically meaningful, dose-and time-dependent increases in the primary endpoint of the 6-minute walk test compared with placebo.</li><li>The company was evaluating whether its investigational therapy improves physical functioning in 148 ambulatory individuals with frailty.</li><li>The therapy is currently being evaluated in multiple indications including hypoplastic left heart syndrome (HLHS) and Alzheimer’s disease (AD).</li></ul>Shares of Longeveron Inc. (LGVN) rose 7% on Wednesday, before paring back gains, after the company announced positive results from the trial of its investigational therapy in age-related clinical frailty.The company said that intravenous laromestrocel improved the physical condition of patients with age-related clinical frailty after nine months, compared to placebo, in a study.LGVN shares traded 9% lower at the time of writing.<h2 class="st-heading-2">Trial Outcomes</h2>The company said that laromestorcel infusions resulted in clinically meaningful, dose-and time-dependent increases in the primary endpoint of the 6-minute walk test compared with placebo. The 6-Minute Walk Test (6MWT) is a submaximal, standardized exercise test measuring the distance a patient can walk on a flat, hard surface in six minutes.“We are highly encouraged by these Phase 2b results that demonstrate the potential of stem cell therapy to improve the condition of patients with aging-related frailty,” <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://investors.longeveron.com/news/News/news-details/2026/Longeveron-Results-of-Phase-2b-Clinical-Trial-Demonstrating-Stem-Cell-Therapy-Improved-Condition-of-Patients-with-Age-Related-Frailty-Published-in-Cell-Stem-Cell/default.aspx">said</a> Joshua M. Hare, Chief Science Officer at Longeveron. “Those with Aging Frailty are disproportionately compromised in their ability to cope with every day and acute stressors, are at high vulnerability to disease and injury, and are at increased risk for poor outcomes and death after surgery.”Laromestrocel, the company’s lead investigational product, is a human bone marrow-derived allogeneic stem cell (MSC) investigational therapy. The company was evaluating whether it improves physical functioning in 148 ambulatory individuals with frailty. The therapy is currently being evaluated in multiple indications including hypoplastic left heart syndrome (HLHS), Alzheimer’s disease (AD), and Pediatric Dilated Cardiomyopathy (DCM).<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around LGVN stock rose from ‘neutral’ to ‘bullish’ territory over the past 24 hours, while message volume rose from ‘normal’ to ‘high’ levels.A Stocktwits user said that positive news from the company never helps the stock price.<stembedurl>https://www.stocktwits.com/Dorps332/message/645856800</stembedurl><a href="https://stocktwits.com/symbol/LGVN">LGVN stock</a> is down by 64% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/why-did-odd-shares-tumble-today/cZRyBHbRIGS">Why Did ODD Shares Tumble More Than 50% Today?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

The Longeveron, Inc. logo appears on a smartphone screen in this illustration photo in Reno, United States, on January 3, 2025. (Photo Illustration by Jaque Silva/NurPhoto via Getty Images)

LGVN Shares Rise After Investigational Therapy Shows Improvement In Age-Related Frailty Study

Longeveron said that intravenous laromestrocel improved the physical condition of patients with age-related clinical frailty after nine months, compared to placebo.

Equity

Longeveron, Inc. is a clinical stage biotechnology company, which engages in the development of cellular therapies for specific aging-related and life-threatening conditions. Its lead product, LOMECEL-B, is a cell-based therapy product, which is derived from culture-expanded medicinal signaling cells that are sourced from bone marrow of young, healthy, adult donors. The company was founded by Joshua M. Hare and Donald M. Soffer on October 9, 2014 and is headquartered in Miami, FL.

Longeveron Inc - Ordinary Shares - Class A

Opendoor ($OPEN)

Strategy ($MSTR)

American Eagle ($AEO)

Ondas Inc. ($ONDS)

The stock that proved the power of the crowd. Fueled by community energy and social momentum, this winner captivated retail investors regardless of what the "experts" or traditional fundamentals had to say.

LGVN
Longeveron Inc - Ordinary Shares - Class A

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest LGVN News

LGVNLongeveron Inc - Ordinary Shares - Class A